Pioglitazone

Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings . Important Limitations of Use Pioglitazone tablets exert its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease .

12.1 Mechanism of Action Pioglitazone is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver.

With Biphasic clearance with 5–16 hr terminal t½ under Pioglitazone maintenance residence kinetics and Systemic oral bioavailability of roughly 73%–85% following first-pass transit bioavailability, Pioglitazone undergoes primary cyp2c8 cytochrome processing paired with glucuronide elimination for pioglitazone and establishes therapeutic activity over initial pharmacodynamic onset within 1–4 hrs (peak cmax) for pioglitazone.

Standard adult regimens span 30 mg/1 Tablet, 15 mg/1 Tablet, 45 mg/1 Tablet, 15mg Tablet, 45mg Tablet. Prescribers screen specifically against initiation in patients with established nyha class iii or iv heart failure .; use in patients with known hypersensitivity to pioglitazone or any other component of pioglitazone tablets., while community micro-logs most frequently note nausea (8.4% of reports), headache (7% of reports), dizziness (5% of reports).